Marcie A. Goldstein

Davis Polk advised the underwriters in connection with a secondary offering of 7,500,000 shares of Class A common stock of Evolent Health, Inc. by certain of Evolent’s existing stockholders…

Davis Polk advised the representatives of the underwriters in connection with the $75.9 million offering of 3,700,000 shares of common stock of REGENXBIO Inc. The common stock is listed on…

Davis Polk advised the active joint book-running managers and representatives of the underwriters in connection with the $90 million follow-on offering of 4,000,000 shares of common stock…

Davis Polk advised the joint book-running managers in connection with the $218.5 million initial public offering of 13,656,250 shares of Class A common stock of Hamilton Lane…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $349 million secondary offering of 10,989,163 common shares of The…

Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of Coherus BioSciences, Inc. The common stock is listed on the NASDAQ…

Davis Polk advised the lead book-running manager and representative of the underwriters in connection with its $101.9 million initial public offering of common stock of Jounce Therapeutics,…

Davis Polk advised the joint book-running managers in connection with a $138 million SEC-registered offering of 4,450,500 shares of common stock of Loxo Oncology, Inc. The common stock is…

Davis Polk advised the joint book-running managers in connection with the approximately $237 million primary offering of 10,000,000 shares of common stock of Summit Materials, Inc. The…

Davis Polk advised the joint book-running managers in connection with the $100.9 million public offering of common stock of Achaogen, Inc. The common stock is listed onthe NASDAQ Global…